DIMERIX LIMITED (DXB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

DXB - DIMERIX LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0

Index: ALL-ORDS

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.52 03 Feb 2026	0.010 OPEN $0.52	1.96% HIGH $0.52	648,294 LOW $0.51

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$0.52

03 Feb
2026

0.010

OPEN

$0.52

1.96%

HIGH

$0.52

648,294

LOW

$0.51

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2026 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	-2.4
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	5.6 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	2.2
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	39.0 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-237.20 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-83.97 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-83.78 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-21.50 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-83.97 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-201.24 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	39.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Total Debt	xxx	xxx	xxx	xxx	xxx	0 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	68 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	25.73

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	0.0 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	0.38 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	-
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	37 M
Research & Development	xxx	xxx	xxx	xxx	xxx	27 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Petra Capital	01/02/2026	1	Buy	$1.46	180.77%	Petra Capital notes Dimerix's 2Q26 4C showed cash of $38.5m, with operating cash outflow easing to $11.1m q/q but still above expectations, partly reflecting the absence of a circa $2m R&D rebate and residual one-off costs. The broker expects burn to moderate now that recruitment for the ACTION 3 FSGS trial is complete and highlights Dimerix remains well funded to progress the trial and commercial readiness. Focus remains on upcoming FDA feedback, which will determine the timing of a blinded statistical powering analysis and whether a 12-month accelerated approval pathway for DMX-200 remains viable. Petra Capital retains a Buy rating and $1.46 target, with forecasts under review. FORECAST Petra Capital forecasts a full year FY26 dividend of 0.00 cents. Petra Capital forecasts a full year FY27 dividend of 0.00 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Petra Capital

01/02/2026

Buy

$1.46

180.77%

Petra Capital notes Dimerix's 2Q26 4C showed cash of $38.5m, with operating cash outflow easing to $11.1m q/q but still above expectations, partly reflecting the absence of a circa $2m R&D rebate and residual one-off costs.

The broker expects burn to moderate now that recruitment for the ACTION 3 FSGS trial is complete and highlights Dimerix remains well funded to progress the trial and commercial readiness.

Focus remains on upcoming FDA feedback, which will determine the timing of a blinded statistical powering analysis and whether a 12-month accelerated approval pathway for DMX-200 remains viable.

Petra Capital retains a Buy rating and $1.46 target, with forecasts under review.

FORECAST
Petra Capital forecasts a full year FY26 dividend of 0.00 cents.
Petra Capital forecasts a full year FY27 dividend of 0.00 cents.

Access Extra Coverage Research History >

DXB STOCK CHART

FNArena News on DXB

Latest Pharmaceuticals & Biotech/Lifesciences News

1	CSL: Buy Trigger Ahead Apr 26 2022 - Technicals

2	Why CSL Fell Sharply Yesterday Dec 17 2021 - Australia

3	Beating The Biotech Blues Sep 14 2021 - International

4	Uncertainty Prevails For CSL Aug 19 2021 - Australia

5	Flying High – Medicinal Marijuana In Australia Jul 26 2021 - Australia

6	Wesfarmers On Drugs? Jul 13 2021 - Australia

7	Is CSL’s Plasma Recovery Now Priced In? Jun 23 2021 - Australia

8	CSL: Buy The Dip Jun 22 2021 - Technicals

9	CSL To Retest Its High? May 25 2021 - Technicals

10	Treasure Chest: CSL Plasma At Turning Point? May 05 2021 - Treasure Chest

Get 2 Weeks free trial

Sign Up

Member Login

DIMERIX LIMITED (DXB)
Share Price Analysis and Chart